DA
GPCR icon

DCF Advisers’s Structure Therapeutics GPCR Stock Holding History

DCF Advisers’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.33M Sell
27,500
-2,500
-8% -$171K 0.35% 49
2025
Q4 		$2.09M Buy
+30,000
New +$1.22M 0.56% 46
2025
Q3 		– Sell
-24,750
Closed -$513K – 108
2025
Q2 		$513K Buy
+24,750
New +$544K 0.24% 68

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

DCF Advisers's GPCR Position: Q1 2026 in Review

DCF Advisers reduced its Structure Therapeutics (GPCR) stake by 8.3% in Q1 2026, selling an estimated $171K and leaving 27,500 shares worth $1.33M. The position accounts for 0.35% of the portfolio, ranked #49.

DCF Advisers first reported a position in GPCR in Q2 2025 and has held it in 3 quarters since. The position peaked at $2.09M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • DCF Advisers held 27,500 shares of Structure Therapeutics worth $1.33M as of Q1 2026.
  • DCF Advisers sold 2,500 Structure Therapeutics shares in Q1 2026, an estimated $171K.
  • Structure Therapeutics made up 0.35% of DCF Advisers's portfolio in Q1 2026, its #49 holding.
  • DCF Advisers first reported a position in Structure Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • DCF Advisers's Structure Therapeutics position peaked at $2.09M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on DCF Advisers's 13F filing for Q1 2026, filed 11 May 2026.